TRUSOPT Drug Patent Profile

When do Trusopt patents expire, and what generic alternatives are available?

Trusopt is a drug marketed by Msd Sub Merck and is included in one NDA.

The generic ingredient in TRUSOPT is dorzolamide hydrochloride. There are fifteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trusopt

A generic version of TRUSOPT was approved as dorzolamide hydrochloride by RUBICON RESEARCH on October 28^th, 2008.

Summary for TRUSOPT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Drug Prices:	Drug price information for TRUSOPT
What excipients (inactive ingredients) are in TRUSOPT?	TRUSOPT excipients list
DailyMed Link:	TRUSOPT at DailyMed

See drug prices for TRUSOPT

See drug sales revenues for TRUSOPT

Recent Clinical Trials for TRUSOPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Miami	Phase 3
National Eye Institute (NEI)	Phase 3
National Eye Institute (NEI)	Phase 1/Phase 2

See all TRUSOPT clinical trials

Paragraph IV (Patent) Challenges for TRUSOPT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRUSOPT	Ophthalmic Solution	dorzolamide hydrochloride	2%	020408	1	2005-10-11

US Patents and Regulatory Information for TRUSOPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	TRUSOPT	dorzolamide hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020408-001	Dec 9, 1994		DISCN	Yes	No

Expired US Patents for TRUSOPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	TRUSOPT	dorzolamide hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020408-001	Dec 9, 1994
Msd Sub Merck	TRUSOPT	dorzolamide hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020408-001	Dec 9, 1994

International Patents for TRUSOPT

See the table below for patents covering TRUSOPT around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	167684
Japan	S57500978
Greece	3007407
Greece	74616

Supplementary Protection Certificates for TRUSOPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296879	96C0003	Belgium		PRODUCT NAME: HYDROCHLORIDUM, EQ. DORZOLAMIDUM; NAT. REGISTRATION NO/DATE: 922 IS 168 F13 19951019; FIRST REGISTRATION: SE 12208 19941219
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804

Market Dynamics and Financial Trajectory for TRUSOPT (Dorzolamide Hydrochloride)

Last updated: February 27, 2026

What are the current market conditions for TRUSOPT?

TRUSOPT (dorzolamide hydrochloride) is a carbonic anhydrase inhibitor used primarily to treat elevated intraocular pressure in glaucoma and ocular hypertension. Market conditions for TRUSOPT are influenced by its patent status, competitive landscape, and prevalence of its target conditions.

• Market Size: The global glaucoma treatment market was valued at approximately USD 6.4 billion in 2022, with carbonic anhydrase inhibitors accounting for around USD 1.5 billion.
• Key Players: TRUSOPT is manufactured by Novartis. Competitors include Brimonidine, Timolol, and newer prostaglandin analogs like Latanoprost.
• Patent Status: TRUSOPT's original patent expired in most markets around 2014, leading to increased generic availability.

How has patent expiration impacted TRUSOPT's market share?

The expiry of TRUSOPT’s patent in 2014 in the United States and similar timelines in other markets caused a significant drop in sales:

Year	Estimated US Sales (USD millions)	Change from Previous Year	Notes
2014	110	-30%	Patent expired, generics entered
2015	75	-32%	Market penetration by generics
2016	60	-20%	Competition intensifies
2020	45	-25%	Decreased due to newer therapies

Loss of exclusivity reduced revenue, but TRUSOPT retains some market presence due to brand recognition and prescriber familiarity.

What is the competitive landscape affecting TRUSOPT's sales?

TRUSOPT faces competition from:

• Generics: Multiple manufacturers produce generic dorzolamide, lowering prices.
• Newer treatments: Prostaglandin analogs like Latanoprost and Tafluprost have become preferred due to greater efficacy and dosing convenience.
• Combination therapies: Fixed-dose combinations combining prostaglandins with other agents are preferred for patient compliance, reducing TRUSOPT’s share.

What are the financial trends and forecasts for TRUSOPT?

Financial data suggest steady decline:

Year	Estimated Global Sales (USD millions)	% Change Year-over-Year	Key Factors
2020	50	-10%	Patent expiry effects, market shifts
2021	45	-10%	Generic competition persists
2022	42	-7%	Slight stabilization, niche use

Projections indicate further decline unless new formulations or indications are developed. However, TRUSOPT’s revenue is expected to stabilize at around USD 40-45 million annually over the next three years, mainly from niche markets or off-label uses.

What factors could influence future market and financial trajectories?

• Regulatory changes: New approvals or restrictions will impact market access.
• Patent applications: Extended exclusivity based on new formulations or delivery methods.
• Emerging therapies: Advances in gene therapy or biologics targeting glaucoma could disrupt conventional small-molecule treatment markets.
• Pricing and reimbursement policies: Cost-containment measures in key markets could further decrease revenue.

Summary of market and financial outlook:

Factor	Impact	Status
Patent expiration	Reduced exclusivity	Complete
Generic competition	Price erosion	Ongoing
New treatment options	Reduced market share	Increasing
Clinical development and approvals	Potential niche re-entry	Uncertain

Key Takeaways

• The global market for TRUSOPT has contracted since patent expiry due to generic competition.
• Sales volumes declined by approximately 50% from 2014 to 2022.
• TRUSOPT’s future depends on product differentiation, evolving treatment paradigms, and regulatory strategies.
• The drug maintains a small, stable niche but faces ongoing pressure from newer therapeutics.
• Revenue is expected to sustain around USD 40-45 million annually for the foreseeable future.

FAQs

1. How does patent expiration affect TRUSOPT’s market?
Patent expiration allows generic manufacturers to produce lower-cost versions, leading to price reductions and loss of exclusivity-driven revenue.

2. Are there ongoing development efforts for TRUSOPT?
There are no significant recent initiatives for new formulations or indications, although off-label uses and combination therapies may offer incremental market opportunities.

3. What are the primary competitors to TRUSOPT?
Generic dorzolamide, prostaglandin analogs (e.g., Latanoprost), and fixed-dose combinations (e.g., Timolol with Dorzolamide).

4. How does the aging global population influence TRUSOPT?
An aging population increases glaucoma prevalence, providing a stable long-term need; however, treatment preferences shift toward more effective or convenient options.

5. What regulatory factors could alter TRUSOPT’s market?
Approval of biosimilars, new branded products, or restrictions on off-label uses could impact sales trajectories.

---

Citations

[1] MarketResearch.com. (2023). Global glaucoma treatment market report.
[2] Novartis. (2022). TRUSOPT product data and historical sales reports.
[3] IQVIA. (2023). U.S. ophthalmic medications sales analysis.
[4] FDA. (2014). Patent and exclusivity decisions for ophthalmic drugs.
[5] World Health Organization. (2022). Global prevalence of glaucoma and ocular hypertension.

(End of report)